AzTrials
AzTrials

TuberculosisNCT00608790

Rapid Diagnosis of Pulmonary Tuberculosis

A study testing Salbutamol and Sodium chloride 5% in people with Tuberculosis, run by University of Cape Town at 1 site in South Africa.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this study is to test whether a saline nebulization (breathing in a mist of moist air through a mask) will help an individual cough up a better sputum sample to test for tuberculosis (TB). Read more about this study

Who is it for?
Ages 12 years and older
Conditions the study is for
Tuberculosis
What is being tested?
Salbutamol and Sodium chloride 5%
Could I receive a placebo?
No, everyone receives an active treatment
How many people
600 participants
Where
1 siteSouth Africa
Study dates
Feb 2008to Apr 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Adolescents and adults with suspected pulmonary tuberculosis who are referred, or self-refer, to health services clinics for investigation for tuberculosis, will be eligible to participate.

Who cannot join

  • Failure to obtain informed consent (including failure to consent for either sputum collection procedures or failure to consent for HIV testing);
  • Age less than 12 years;
  • A history of asthma;
  • A history of heart disease;
  • A history of cardiac arrhythmia;
  • Inability to tolerate sputum induction procedures;
Show all 10Show fewer
  • Inability to return for study follow-up visit;
  • Need for hospital-based in-patient treatment or supplemental oxygen therapy;
  • Other acute or chronic lung disease that may compromise lung function;
  • Current anti-tuberculous therapy.

Trial locations and contacts

1 site in 1 country.

Mark Hatherill contact

+27 21 4047618

South Africa1 site, 1 recruiting
  • University of Cape Town

    Cape Town

    Mark Hatherill, MD, +27214047618, mark.hatherill@uct.ac.za

    Recruiting

Other trials in South Africa

About this study

Official title: Diagnostic Yield of Induced Sputum for Rapid Diagnosis of Pulmonary Tuberculosis

The purpose of this study is to test whether a saline nebulization (breathing in a mist of moist air through a mask) will help an individual cough up a better sputum sample to test for tuberculosis (TB). In addition, this study will test whether samples obtained with saline nebulization are better at finding TB in people with HIV infection. The study will enroll up to 600 individuals, aged 12 and older, with suspected pulmonary TB. Participants will be asked to cough up a sample of sputum into a container. Then, participants will be asked to breathe a mist of moist air from an oxygen mask followed by moist salty air, which will help individuals to cough up a second sputum sample. This mist of moist air will contain salbutamol, a medicine to help open up the airways. The sputum samples will be sent to a laboratory to test for TB. Additionally, participants will be tested for HIV with a blood sample collection. Participants will be involved in study related procedures for up to 61 days.

Read the detailed description

Early case detection, treatment, and prompt household contact investigation, depend on rapid microbiological confirmation, by direct smear microscopy of acid-fast bacilli, in patients with suspected pulmonary tuberculosis. Since delayed diagnosis may result in death due to lack of appropriate therapy, rapid microbiological diagnosis is especially critical in HIV-infected persons. Improved rapid diagnostic methods are also crucial for the success of epidemiological studies; trials of preventative interventions, such as novel vaccines; and therapeutic interventions, since the diagnostic endpoints of such trials may require microbiological confirmation of tuberculosis. In clinical practice, early therapeutic intervention might reduce the risk of death, especially in patients co-infected with HIV. In this study, researchers propose to test a simple diagnostic modality for rapid diagnosis of pulmonary tuberculosis in HIV-infected and HIV-uninfected adolescents and adults. Researchers will test whether induced sputum will improve the diagnostic yield of smear positive tuberculosis. This low-cost technology augments spontaneous sputum production by inhalation of a nebulized saline solution. The primary objective of this study is to quantify and compare the diagnostic yield of smear positive tuberculosis from induced sputum, with that of routine sputum, in HIV-infected patients with suspected tuberculosis. Researchers believe that induced sputum will increase the diagnostic yield from direct smear microscopy in this patient population. The secondary objective of the study is to quantify and compare the diagnostic yield of smear positive tuberculosis from induced sputum, with that of routine sputum, in all patients with suspected tuberculosis, regardless of HIV status. Researchers believe that induced sputum will increase the diagnostic yield from direct smear microscopy in all patients in this population, regardless of HIV status. Approximately 1200 individuals (male or female gender), aged 12 years and older, with suspected pulmonary tuberculosis, will be screened in order to enroll 600 eligible participants at 2 district health services clinics near the town of Worcester, Western Cape Province, South Africa. Informed consent for participation will be sought from adolescents and adults with suspected pulmonary tuberculosis who present to public sector community health services for investigation. A rapid HIV test, with pre- and post-test counseling, will be performed. A routine spontaneous expectorated sputum sample and an induced sputum sample (obtained after nebulization of sterile 5% saline via mask) will be collected. A second routine sputum will be collected on the following morning. Direct smear microscopy and mycobacterial culture of sputum will be performed in an accredited microbiology laboratory. HIV rapid test results will be used to classify participants for evaluation of the primary outcome, positive direct smear microscopy, and the secondary outcome, positive culture of M. tuberculosis. Diagnostic yields for each routine and induced sputum sample will be calculated, as a proportion of all patients who are culture-positive for M. tuberculosis, and compared in a pair-wise and sequential manner. Results will be reported as differences in yield and 95% confidence intervals for the difference in those proportions. The primary endpoint will be sputum direct smear microscopy positive for acid-fast bacilli. The secondary endpoint will be sputum culture positive for Mycobacterium tuberculosis. Study duration will be 4 years with individual subject participation approximately 8 weeks.

Conditions
Tuberculosis
Being tested
Salbutamol, Sodium chloride 5%
Keywords
Tuberculosis, TB, Mycobacterium tuberculosis, children, South Africa
Medical subject headings
Tuberculosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SalbutamolDrug

    Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.

  • Sodium chloride 5%Drug

    30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.

Study groups in NCT00608790
Study groupRoleWhat they receive
1ExperimentalNot described
Receives: Drug: Salbutamol; Drug: Sodium chloride 5%

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sputum direct smear positive for acid-fast bacilli.

    Measured: Day 56 +

Secondary outcomes (1)
  1. Sputum culture positive for Mycobacterium tuberculosis.

    Measured: Day 56 +

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Feb 2008 (estimated)
  2. Study startFeb 2008
  3. Primary completionDec 2012 (estimated)
  4. Study completionApr 2013 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00608790
Sponsor's protocol ID
07-0058
Other IDs
5R01AI075603-04
Status last verified
Jul 2012
First submitted
31 Jan 2008
Last updated
24 Jul 2012
Results posted
No
Data monitoring committee
No

Publications

  • Geldenhuys HD, Whitelaw A, Tameris MD, Van As D, Luabeya KK, Mahomed H, Hussey G, Hanekom WA, Hatherill M. A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community. Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2259-66. doi: 10.1007/s10096-014-2198-4. Epub 2014 Jul 15.

    PubMed 25022447

Questions about this trial

What is this clinical trial studying?

A study testing Salbutamol and Sodium chloride 5% in people with Tuberculosis, run by University of Cape Town at 1 site in South Africa.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Jul 2012. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mark Hatherill (+27 21 4047618), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sputum direct smear positive for acid-fast bacilli. (time frame: Day 56 +). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00608790, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2012; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in